Popular Stories

Earnings Outlook for Inovio Pharmaceuticals

INO) will release its latest earnings report. Check out Benzinga’s preview to understand the implications.

Earnings and Revenue

Analysts covering Inovio Pharmaceuticals have modeled for quarterly EPS of $-0.17 on revenue of $2.61 million. In the same quarter last year, Inovio Pharmaceuticals announced EPS of $-0.3 on revenue of $135.67 thousand. If the company were to match the consensus estimate, earnings would be up 43.33%. Here’s how the company’s EPS has stacked up against analyst estimates in the past:

Quarter Q1 2020 Q4 2020 Q3 2019 Q2 2019
EPS Estimate -0.22 -0.24 -0.26 -0.27
EPS Actual -0.26 -0.38 -0.25 -0.30
Revenue Estimate 1.91 M 2.32 M 3.93 M 5.66 M
Revenue Actual 1.33 M 279.00 K 866.86 K 135.67 K

Stock Performance

For a full 12 months, the return has risen by 756.04%. Given that these returns are generally positive, long-term shareholders are probably relaxed going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.

View more earnings on INO” data-reactid=”23″>View more earnings on INO

https://www.webcaster4.com/Webcast/Page/2021/36286” data-reactid=”24″>Don’t be surprised to see the stock move on comments made during its conference call. Inovio Pharmaceuticals is scheduled to hold the call at 16:30:00 ET and can be accessed here: https://www.webcaster4.com/Webcast/Page/2021/36286

View Article Origin Here

Related Articles

Back to top button